

**McCreadie Group, Inc.**

## **NEWS RELEASE**

Contact: Jennifer Drabing  
jennifer@mccreadiegroup.com  
734-661-7955

### **McCreadie Group Announces Strategic Partnership with The Leukemia & Lymphoma Society (LLS)**

*Clinical trial studying therapies for patients with acute myeloid leukemia (AML) will benefit from the coordination of data between leading academic centers.*

**June 09, 2020 – ANN ARBOR, MI** – McCreadie Group, Inc. is partnering with The Leukemia & Lymphoma Society (LLS) to support the organization’s Beat AML® Master Clinical Trial. McCreadie Group will now provide study drug disposition and monitoring activity data to the LLS from Vestigo® client sites participating in the clinical trial.

The Beat AML® Master Clinical Trial is a groundbreaking collaborative trial testing numerous novel targeted therapies simultaneously across multiple academic centers for patients with acute myeloid leukemia (AML). AML is one of the deadliest blood cancers, and the most commonly diagnosed form of leukemia in adults.

Essential investigational drug product data for each of the individual protocols in the trial is gathered from all Vestigo client sites participating in the Beat AML® Master Clinical Trial. The data provided by McCreadie Group allows researchers to follow the status of a study drug from the time it arrives at a site until its final disposition is recorded and provides LLS with remote visibility to allow dashboard data analytics for key monitoring oversight activities.

Rick Malone, Pharm.D., MHA, the Business Development Executive who is leading the project for McCreadie Group explained: “Providing this data allows the research team to complete data capture more efficiently along with enabling remote identification of potential monitoring gaps. We hope our partnership results in increased awareness of how utilization of technology can open the window to what’s going on at sites... even when access to facilities is limited.”

#### **About McCreadie Group**

The McCreadie Group, Inc. was founded in 2004 to provide software solutions for pharmacy applications in healthcare, research, and educational settings. McCreadie Group’s goal is to drive improvements in quality, efficiency, safety, and compliance in the pharmacy profession by delivering innovative software and consultative support. To learn more about McCreadie Group and its products, visit [www.mccreadiegroup.com](http://www.mccreadiegroup.com).

#### **About Vestigo**

Vestigo is the Investigational Drug Service (IDS) industry standard software solution used in major research institutions across the nation as well non-traditional and smaller research sites. It automates the manual data capture experienced in IDS and increases safety, compliance, and efficiency. Vestigo contributes to accelerated drug discovery and facilitates more efficient study monitoring by bridging data gaps and optimizing the pharmaceutical supply chain. “We are proud to have 70% of NIH-funded research institutions and almost 80% of NCI-designated cancer centers as loyal clients and look forward to doing great things together with LLS,” stated Elena Stegemann, McCreadie Group’s Chief Operating Officer.

**McCreadie Group, Inc.**

**NEWS RELEASE**

Contact: Jennifer Drabing  
jennifer@mccreadiegroup.com  
734-661-7955

**About The Leukemia & Lymphoma Society**

The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. The LLS mission: cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. Founded in 1949 and headquartered in Rye Brook, New York, LLS has chapters throughout the United States and Canada. To learn more, visit [www.LLS.org](http://www.LLS.org).

**# # # #**